ライフサイエンスコーパス: dextroamphetamine

1 opamine release induced by l-DOPA and l-DOPA+dextroamphetamine.

2 and after dopamine transporter blockade with dextroamphetamine.

3 ntially to treatment with methylphenidate or dextroamphetamine.

4 ation for improved cognitive efficiency with dextroamphetamine.

5 mes (3-5 and 6-10 h) following 0.5 mg kg(-1) dextroamphetamine.

6 Dextroamphetamine (0.25 mg/kg) or placebo was administer

7 Dextroamphetamine (20 mg) or placebo administration at 4

8 LAC)-controlled study of the effects of oral dextroamphetamine (AMPH, 0.25 mg/kg) treatment on brain

9 ve psychostimulant (e.g., methylphenidate or dextroamphetamine/amphetamine combination) dose.

10 We studied the effects of dextroamphetamine, an indirect monoaminergic agonist, on

11 lness, and DA transporter inhibitors such as dextroamphetamine and methylphenidate are effective for

12 dings in this study suggest that amphetamine/dextroamphetamine and methylphenidate exposure in utero

13 In unadjusted analyses, amphetamine/dextroamphetamine and methylphenidate exposure were asso

14 ratios were estimated comparing amphetamine/dextroamphetamine and methylphenidate to no exposure.

15 aily life, we discover that methylphenidate, dextroamphetamine, and modafinil cause knapsack value at

16 er ventral striatal dopaminergic response to dextroamphetamine, and that an inability to attenuate ve

17 e sulfate, dextro-, levoamphetamine sulfate, dextroamphetamine aspartate, levoamphetamine aspartate,

18 e behaviours, participated in a single-blind dextroamphetamine challenge (oral; 0.43 mg/kg) in an OFF

19 al behavioral sensitization mechanisms after dextroamphetamine challenge is seen in subjects with sch

20 like movements would increase after repeated dextroamphetamine challenge to the dopaminergic system.

21 were administered both placebo and repeated dextroamphetamine challenges.

22 use of ADHD stimulants (methylphenidate and dextroamphetamine) (chi(2) = 5.00, P = 0.01).

23 rs sensitive to the pro-cognitive effects of dextroamphetamine (d-amp) (10 or 20 mg) in healthy adult

24 Amphetamine doses were converted to dextroamphetamine equivalents and divided into terciles.

25 observed; high doses of amphetamines (>30 mg dextroamphetamine equivalents) were associated with 5.28

26 73 501 stimulant-unexposed, 2372 amphetamine/dextroamphetamine-exposed, and 337 methylphenidate-expos

27 96 771 stimulant-unexposed, 4693 amphetamine/dextroamphetamine-exposed, and 786 methylphenidate-expos

28 stment for measured confounders, amphetamine/dextroamphetamine exposure was not associated with any o

29 However, the effect of dextroamphetamine (i.e., dextroamphetamine vs placebo) o

30 portion of the left inferior frontal gyrus, dextroamphetamine increased rCBF during WCST but decreas

31 ise and region of interest analyses revealed dextroamphetamine-induced endogenous dopamine release lo

32 Dispensing of amphetamine/dextroamphetamine or methylphenidate in the second half

33 ne aspartate, levoamphetamine aspartate, and dextroamphetamine saccharate) in the treatment of adult

34 receptor uptake in a placebo-controlled oral dextroamphetamine sequence.

35 D2-like receptor ligand, in the placebo and dextroamphetamine state.

36 ty, adverse event, side effect, amphetamine, dextroamphetamine, stimulant, lisdexamfetamine, and meth

37 mixed amphetamine salts compound (Adderall, dextroamphetamine sulfate, dextro-, levoamphetamine sulf

38 These findings illustrate that dextroamphetamine tends to "focus" neural activity, to h

39 This capacity of dextroamphetamine to induce cognitively specific signal

40 This was abrogated by acute dextroamphetamine treatment, consistent with PNKD3-affec

41 ever, the effect of dextroamphetamine (i.e., dextroamphetamine vs placebo) on task-dependent rCBF act

42 osite to that seen in a previous study using dextroamphetamine, we postulated a dopaminergic mechanis